BioCentury
ARTICLE | Product Development

Mesoblast to seek advancement of heart failure cell therapy on 60% composite CV outcomes reduction

January 12, 2021 3:33 AM UTC

A composite analysis showing reductions in cardiac death, stroke and heart attack in Mesoblast’s Phase III heart failure trial appears to have allayed investor concerns following the December disclosure that cell therapy didn’t meet the study’s primary endpoint.

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) gained $2.74 (32%) $11.40 in New York and A$0.32 (14%) to A$2.56 Monday after announcing  a single transendocardial injection of Revascor rexlemestrocel-L lowered three-point major adverse cardiovascular events (MACE) — a combination of heart attacks, strokes and cardiac deaths — incidence by 30% vs. a control procedure (20.6% vs. 30%, p=0.027) in the DREAM-HF trial. The three CV outcomes were prespecified. ...

BCIQ Company Profiles

Mesoblast Ltd.